Rubraca (rucaparib) — Medica

Initial criteria

• age ≥ 18 years
• Patient has metastatic castration resistant prostate cancer
• Patient has BRCA mutation-positive (germline and/or somatic) disease
• Patient meets ONE of the following (i or ii): i. The medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog; OR ii. Patient has had a bilateral orchiectomy
• Patient has been previously treated with at least one androgen receptor-directed therapy

Approval duration

1 year